TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06244979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
Description: 100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
Study: NCT05414474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 500 mg
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 80 mg
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Afternoon
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
Study: NCT06529614

Intervention type: OTHER
Intervention: In-situ detection for Micro-RNA
Description: a new in-situ detection methods for Micro-RNA

Intervention type: OTHER
Intervention: In-situ detection for Micro-RNA
Description: a new in-situ detection methods for Micro-RNA
Study: NCT05564104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
Study: NCT05751941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg of Enzalutamide will be given orally daily ending at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg of Apalutamide will be given orally daily ending at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
Study: NCT05477134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus
Description: On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
Study: NCT06023589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Participants will be receiving subcutaneous injection of tezepelumab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be receiving subcutaneous injection of matching placebo
Study: NCT05627570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy, balanced Diet A
Description: Healthy, balanced diet following Eatwell Guide recommendations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy, balanced Diet A
Description: Healthy, balanced diet following Eatwell Guide recommendations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy, balanced Diet B
Description: Healthy, balanced diet following Eatwell Guide recommendations

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy, balanced Diet B
Description: Healthy, balanced diet following Eatwell Guide recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural support intervention
Description: Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural support intervention
Description: Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
Study: NCT04796948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
Description: irinotecan liposome in combination with oxaliplatin and 5-FU/LV
Study: NCT05918523

Intervention type: BIOLOGICAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: No interventions in this trial
Study: NCT06138379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: 1st Experimental Group
Description: Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: 2nd Experimental Group
Description: Individuals will be sent relevant educational videos after liver transplantation and asked to watch them.
Study: NCT05382923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: 3 consecutive days of 1 hour bright light

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light + Exercise + Melatonin
Description: 3 consecutive days of bright light, exercise, and melatonin

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 3 consecutive days of dim red light + light stretching + placbo
Study: NCT05164809

Intervention type: DEVICE
Intervention: Application of novel electrodes
Description: Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
Study: NCT05305209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
Study: NCT06140069

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders.
Study: NCT05225688

Intervention type: BEHAVIORAL
Intervention: Bike exertion test
Description: maximal exercise test

Intervention type: BEHAVIORAL
Intervention: Bike exertion test
Description: maximal exercise test

Intervention type: BEHAVIORAL
Intervention: Bike exertion test
Description: maximal exercise test
Study: NCT06253949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ligation of inferior mesenteric artery in colorectal cancer
Description: This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ligation of inferior mesenteric artery in colorectal cancer
Description: This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
Study: NCT05824273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LungTalk
Description: LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored intervention - Standard of practice
Description: ACS Lung Screening Informational Video
Study: NCT04551092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVR
Description: a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
Study: NCT04895033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsibility condition
Description: During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
Study: NCT05780294

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lobaplatin
Description: 30mg/m2, used on the 1st and 28th day of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: 30mg/m2, used on the 1st and 28th day of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucogen
Description: 40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
Study: NCT01909414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA Vaccine
Description: DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA GEO-D03
Description: Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA/HIV62B Vaccine
Description: Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
Study: NCT04765735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)
Description: SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)
Description: SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
Study: NCT06514963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9813
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9813
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06041516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-701
Description: ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
Study: NCT05849181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moona Device
Description: Moona Device pillow pad

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Moona Device
Description: Inactive Moona Device pillow pad
Study: NCT06490146

Intervention type: OTHER
Intervention: No intervention
Description: this is an observational study
Study: NCT05774041

Intervention type: DEVICE
Intervention: SIS System
Description: FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
Study: NCT06139224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 day prebiotic consumption
Description: 20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 day prebiotic consumption
Description: 20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.
Study: NCT05386108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 300 mg, 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 300 mg, 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 300 mg, 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: 300 mg, 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg, 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg, 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg, 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg, 150 mg
Study: NCT06013241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Film-coated tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Nasal spray suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Nasal spray suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Nasal spray suspension.
Study: NCT06648278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation Program
Description: Online health tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life (QOL) Assessment
Description: Online surveys to assess QOL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05624528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: catechol-O-methyl transferase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine
Study: NCT04741776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Enhancement Skills Training
Description: Family therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem-Solving Individual Therapy
Description: Individual therapy
Study: NCT05850468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl infusion after general anesthesia and erector spinea block
Description: intraoperative opioid infusion in active comparative group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine 2% and dextometometidine infusion after general anesthesia and erector spinea block
Description: intraoperative non opioid infusion in experimental group
Study: NCT05203120

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: All patients will receive proton therapy 67.5Gy/15fx
Study: NCT05042089

Intervention type: OTHER
Intervention: No intervention will be applied.
Description: The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.

Intervention type: OTHER
Intervention: No intervention will be applied.
Description: The preoperative imaging of the participants, who were grouped according to the postoperative pathology results, will be examined.
Study: NCT05435755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAESCs treatment
Description: Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: 2 times placebo (normal saline) injections as control group
Study: NCT04760522

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WGS Diagnostic: Blood take for genetic diagnostic
Description: Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).
Study: NCT06383780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GP combined with Tislelizumab
Description: Gemcitabine combined with cisplatin regimen combined with Tislelizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC combined with Tislelizumab
Description: cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab
Study: NCT04647032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Transcranial alternating current stimulation (tACS) will be applied across the prefrontal cortex near electrodes coordinates AF3/AF4
Study: NCT06451419

Intervention type: OTHER
Intervention: Tests on non motor symptoms
Description: Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.

Intervention type: OTHER
Intervention: Tests on non motor symptoms
Description: Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.
Study: NCT05940376

Intervention type: DRUG
Intervention: rapid acting insulin
Description: Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
Study: NCT04612946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Telemedicine LCS Counseling Visit
Description: Patients in the intervention arm will be invited to complete a telemedicine LCS counseling visit, and asked for permission to be referred directly to the LCS navigator to help schedule an appointment. They will also be given the option to directly contact the LCS navigator. Telemedicine counseling visits will be conducted using established clinical procedures for virtual or telephone visits at Penn Medicine. In accordance with reimbursement policies for lung cancer screening, these visits will be conducted by a physician or nurse practitioner within the Lung Cancer Screening Program at Penn Medicine. Counseling visits are covered without co-pay as standalone visits according to USPSTF guidelines and costs will not be covered by the study. LCS is an evidence-based practice and considered standard of care for those who are eligible and desire to be screened. Clinicians retain full control on how to conduct LCS counseling or LDCT in this trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care arm will be provided with contact information for the Penn LCS Program and encouraged to discuss LCS with their providers.